AstraZeneca: Imfinzi Shows Efficacy in Treating Small-Cell Lung Cancer

Date : 09/09/2019 @ 8:27AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7258.0  29.0 (0.40%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca: Imfinzi Shows Efficacy in Treating Small-Cell Lung Cancer

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Astrazeneca Charts.

By Carlo Martuscelli


AstraZeneca PLC (AZN.LN) said Monday that a phase 3 clinical trial of drug Imfinzi showed the drug was able to improve survival rates in patients with small-cell lung cancer.

The British pharmaceutical company said that Imfinzi combined with chemotherapy showed a clinically meaningful improvement in overall survival for patients with untreated extensive-stage small-cell lung cancer when compared with standard chemotherapy.

AstraZeneca said that the treatment reduced the risk of death by 27%, with a median overall survival of 13 months versus 10.3 months for the standard of care.

In the study, titled Caspian, 33.9% of patients treated with Imfinzi reached the 18-month survival mark, compared with 24.7% for chemotherapy alone.

Small-cell lung cancer is an aggressive and fast-spreading cancer.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

September 09, 2019 04:12 ET (08:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191209 03:46:32